260 related articles for article (PubMed ID: 17449018)
21. The human CASQ2 mutation K206N is associated with hyperglycosylation and altered cellular calcium handling.
Kirchhefer U; Wehrmeister D; Postma AV; Pohlentz G; Mormann M; Kucerova D; Müller FU; Schmitz W; Schulze-Bahr E; Wilde AA; Neumann J
J Mol Cell Cardiol; 2010 Jul; 49(1):95-105. PubMed ID: 20302875
[TBL] [Abstract][Full Text] [Related]
22. Ablation of HRC alleviates cardiac arrhythmia and improves abnormal Ca handling in CASQ2 knockout mice prone to CPVT.
Liu B; Ho HT; Brunello L; Unudurthi SD; Lou Q; Belevych AE; Qian L; Kim DH; Cho C; Janssen PM; Hund TJ; Knollmann BC; Kranias EG; Györke S
Cardiovasc Res; 2015 Nov; 108(2):299-311. PubMed ID: 26410369
[TBL] [Abstract][Full Text] [Related]
23. Clinical phenotype and functional characterization of CASQ2 mutations associated with catecholaminergic polymorphic ventricular tachycardia.
di Barletta MR; Viatchenko-Karpinski S; Nori A; Memmi M; Terentyev D; Turcato F; Valle G; Rizzi N; Napolitano C; Gyorke S; Volpe P; Priori SG
Circulation; 2006 Sep; 114(10):1012-9. PubMed ID: 16908766
[TBL] [Abstract][Full Text] [Related]
24. Probing cationic selectivity of cardiac calsequestrin and its CPVT mutants.
Bal NC; Jena N; Sopariwala D; Balaraju T; Shaikh S; Bal C; Sharon A; Gyorke S; Periasamy M
Biochem J; 2011 Apr; 435(2):391-9. PubMed ID: 21265816
[TBL] [Abstract][Full Text] [Related]
25. Impaired Dynamic Sarcoplasmic Reticulum Ca Buffering in Autosomal Dominant CPVT2.
Wleklinski MJ; Kryshtal DO; Kim K; Parikh SS; Blackwell DJ; Marty I; Iyer VR; Knollmann BC
Circ Res; 2022 Sep; 131(8):673-686. PubMed ID: 36102198
[TBL] [Abstract][Full Text] [Related]
26. Modulation of SR Ca release by luminal Ca and calsequestrin in cardiac myocytes: effects of CASQ2 mutations linked to sudden cardiac death.
Terentyev D; Kubalova Z; Valle G; Nori A; Vedamoorthyrao S; Terentyeva R; Viatchenko-Karpinski S; Bers DM; Williams SC; Volpe P; Gyorke S
Biophys J; 2008 Aug; 95(4):2037-48. PubMed ID: 18469084
[TBL] [Abstract][Full Text] [Related]
27. Patient-Specific Drug Screening Using a Human Induced Pluripotent Stem Cell Model of Catecholaminergic Polymorphic Ventricular Tachycardia Type 2.
Maizels L; Huber I; Arbel G; Tijsen AJ; Gepstein A; Khoury A; Gepstein L
Circ Arrhythm Electrophysiol; 2017 Jun; 10(6):. PubMed ID: 28630169
[TBL] [Abstract][Full Text] [Related]
28. Neuronal Na+ channel blockade suppresses arrhythmogenic diastolic Ca2+ release.
Radwański PB; Brunello L; Veeraraghavan R; Ho HT; Lou Q; Makara MA; Belevych AE; Anghelescu M; Priori SG; Volpe P; Hund TJ; Janssen PM; Mohler PJ; Bridge JH; Poelzing S; Györke S
Cardiovasc Res; 2015 Apr; 106(1):143-52. PubMed ID: 25538156
[TBL] [Abstract][Full Text] [Related]
29. Suppression of ryanodine receptor function prolongs Ca2+ release refractoriness and promotes cardiac alternans in intact hearts.
Zhong X; Sun B; Vallmitjana A; Mi T; Guo W; Ni M; Wang R; Guo A; Duff HJ; Gillis AM; Song LS; Hove-Madsen L; Benitez R; Chen SR
Biochem J; 2016 Nov; 473(21):3951-3964. PubMed ID: 27582498
[TBL] [Abstract][Full Text] [Related]
30. Modulation of sarcoplasmic reticulum calcium release by calsequestrin in cardiac myocytes.
Györke S; Györke I; Terentyev D; Viatchenko-Karpinski S; Williams SC
Biol Res; 2004; 37(4):603-7. PubMed ID: 15709687
[TBL] [Abstract][Full Text] [Related]
31. Linking calsequestrin to lumenal control of SR Ca2+ release.
Shannon TR
Circ Res; 2007 Sep; 101(6):539-41. PubMed ID: 17872471
[No Abstract] [Full Text] [Related]
32. A novel heterozygous mutation in cardiac calsequestrin causes autosomal dominant catecholaminergic polymorphic ventricular tachycardia.
Gray B; Bagnall RD; Lam L; Ingles J; Turner C; Haan E; Davis A; Yang PC; Clancy CE; Sy RW; Semsarian C
Heart Rhythm; 2016 Aug; 13(8):1652-60. PubMed ID: 27157848
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and potency of class I antiarrhythmic drugs for suppression of Ca2+ waves in permeabilized myocytes lacking calsequestrin.
Galimberti ES; Knollmann BC
J Mol Cell Cardiol; 2011 Nov; 51(5):760-8. PubMed ID: 21798265
[TBL] [Abstract][Full Text] [Related]
34. Familial hypertrophic cardiomyopathy-linked mutant troponin T causes stress-induced ventricular tachycardia and Ca2+-dependent action potential remodeling.
Knollmann BC; Kirchhof P; Sirenko SG; Degen H; Greene AE; Schober T; Mackow JC; Fabritz L; Potter JD; Morad M
Circ Res; 2003 Mar; 92(4):428-36. PubMed ID: 12600890
[TBL] [Abstract][Full Text] [Related]
35. Unexpected structural and functional consequences of the R33Q homozygous mutation in cardiac calsequestrin: a complex arrhythmogenic cascade in a knock in mouse model.
Rizzi N; Liu N; Napolitano C; Nori A; Turcato F; Colombi B; Bicciato S; Arcelli D; Spedito A; Scelsi M; Villani L; Esposito G; Boncompagni S; Protasi F; Volpe P; Priori SG
Circ Res; 2008 Aug; 103(3):298-306. PubMed ID: 18583715
[TBL] [Abstract][Full Text] [Related]
36. Sarcoplasmic reticulum calcium overloading in junctin deficiency enhances cardiac contractility but increases ventricular automaticity.
Yuan Q; Fan GC; Dong M; Altschafl B; Diwan A; Ren X; Hahn HH; Zhao W; Waggoner JR; Jones LR; Jones WK; Bers DM; Dorn GW; Wang HS; Valdivia HH; Chu G; Kranias EG
Circulation; 2007 Jan; 115(3):300-9. PubMed ID: 17224479
[TBL] [Abstract][Full Text] [Related]
37. Viral delivered gene therapy to treat catecholaminergic polymorphic ventricular tachycardia (CPVT2) in mouse models.
Kurtzwald-Josefson E; Yadin D; Harun-Khun S; Waldman M; Aravot D; Shainberg A; Eldar M; Hochhauser E; Arad M
Heart Rhythm; 2017 Jul; 14(7):1053-1060. PubMed ID: 28336343
[TBL] [Abstract][Full Text] [Related]
38. Calsequestrin 2 deletion causes sinoatrial node dysfunction and atrial arrhythmias associated with altered sarcoplasmic reticulum calcium cycling and degenerative fibrosis within the mouse atrial pacemaker complex1.
Glukhov AV; Kalyanasundaram A; Lou Q; Hage LT; Hansen BJ; Belevych AE; Mohler PJ; Knollmann BC; Periasamy M; Györke S; Fedorov VV
Eur Heart J; 2015 Mar; 36(11):686-97. PubMed ID: 24216388
[TBL] [Abstract][Full Text] [Related]
39. Channel Activity of Cardiac Ryanodine Receptors (RyR2) Determines Potency and Efficacy of Flecainide and R-Propafenone against Arrhythmogenic Calcium Waves in Ventricular Cardiomyocytes.
Savio-Galimberti E; Knollmann BC
PLoS One; 2015; 10(6):e0131179. PubMed ID: 26121139
[TBL] [Abstract][Full Text] [Related]
40. Alpha blockade potentiates CPVT therapy in calsequestrin-mutant mice.
Kurtzwald-Josefson E; Hochhauser E; Bogachenko K; Harun-Khun S; Katz G; Aravot D; Seidman JG; Seidman CE; Eldar M; Shainberg A; Arad M
Heart Rhythm; 2014 Aug; 11(8):1471-9. PubMed ID: 24768611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
